David A. Siegel Dyne Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 13,600 shares of DYN stock, worth $463,624. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,600
Previous 18,000
24.44%
Holding current value
$463,624
Previous $239,000
61.51%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding DYN
# of Institutions
176Shares Held
87.1MCall Options Held
130KPut Options Held
209K-
Atlas Venture Life Science Advisors, LLC8.02MShares$273 Million28.49% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$267 Million31.49% of portfolio
-
Black Rock Inc. New York, NY5.39MShares$184 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.56MShares$155 Million4.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.25MShares$145 Million0.02% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.76B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...